Latest news and press releases about PAVmed Inc. (PAVM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay.
Price
| Price | $3.92 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.70 |
| EV / EBITDA | -2.65 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -33.51% |
| Return on Invested Capital | -72.77% |
| Return on Assets | -30.06% |
| Gross Margin | -254.46% |
| Operating Margin | -23842.86% |
| Net Margin | -10794.64% |
Related companies: ADVB · APVO · BMRA · BNR · DHAI · HSCS · IINN
Explore sector: Healthcare · Medical - Devices
More sections of PAVM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks